[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dystrophia-myotonica-1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dystrophia-myotonica-1":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100624915","evaluation-of-the-role-of-mir-1-in-the-pathogenesis-and-as-a-biomarker-in-muscular-dystrophies-and-congenital-myopathies-100624915",false,"NCT07415837","Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies","Dystro-miR1","Inclusion Criteria:\n\n* Age: Participants must be older than 2 years of age\n* Consent: Participants (or their legal guardians) must provide free and informed consent,. For children, the consent is oral for those under 6 years old and written for those over 6,.\n* Social Security: Every participant must be affiliated with the French social security system.\n* Participants must have a diagnosed neuromuscular pathology : the eligible pathologies are Myotonic Dystrophy Type 1 (DM1 or Steinert's disease), Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (DMB), or congenital myopathies or are healthy participants.\n\nExclusion Criteria:\n\n* Refusal to participate expressed by the subject or their parental authority.\n* Engaging in intense and unusual physical effort within 10 days before the blood draw.\n* Current use of any treatment with systemic, muscular, or cardiac effects that could interfere with the study's biological results.\n* Subjects or their legal guardians who are under tutelage, curatorship, deprived of liberty, or under judicial protection.\n* Women who are pregnant or breastfeeding.\n* The presence of an additional pathology that, in the judgment of the clinician, could interfere with the biological findings",true,"ALL","2 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases.\n\nMicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease.\n\nThe main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities:\n\n1. Patients with Duchenne or Becker muscular dystrophy (DMD\u002FDMB).\n2. Patients with Myotonic Dystrophy Type 1 (Steinert's disease).\n3. Patients with congenital myopathies.\n4. Healthy volunteers (control group). The main objective is to assess if miR-1 levels can accurately show how a muscular disease is progressing.",[27,28,29,30],"Duchenne \u002F Becker Muscular Dystrophy","Dystrophia Myotonica 1","Congenital Myopathies","Healthy Participants",[32,33,34],"biomarkers","neuromuscular diseases","micro-RNAs","RECRUITING","2026-02-24",{"date":38,"type":39},"2026-02-25","ACTUAL",{"date":41,"type":39},"2026-02-11",{"date":43,"type":21},"2029-03",{"name":45,"class":46},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":47},"100239721","myotonic-dystrophy-family-registry-100239721","NCT02398786","Myotonic Dystrophy Family Registry","MDFR","Inclusion Criteria:\n\n* Diagnosed with congenital, juvenile-onset or adult onset DM1 or DM2 (confirmed by clinical exam or genetic test)\n\nExclusion Criteria:\n\n* Not diagnosed with DM, unaffected family members",{"count":56,"type":21},3500,"5 Years","OBSERVATIONAL","The Myotonic Dystrophy Family Registry (MDFR) is an online, patient-entered database that collects information on myotonic dystrophy (DM) to aid researchers in developing new, effective treatments and help identify participants for research studies and clinical trials.",[61,62,63,64,65,28,66,67,68,69,70,71,72,73,74,75],"Myotonic Dystrophy","Congenital Myotonic Dystrophy","Myotonic Dystrophy 1","Myotonic Dystrophy 2","Dystrophia Myotonica","Dystrophia Myotonica 2","Myotonia Dystrophica","Myotonic Dystrophy, Congenital","Myotonic Myopathy, Proximal","PROMM (Proximal Myotonic Myopathy)","Proximal Myotonic Myopathy","Steinert Disease","Steinert Myotonic Dystrophy","Steinert's Disease","Myotonia Atrophica","2024-11-19",{"date":78,"type":39},"2024-11-21",{"date":80,"type":4},"2013-02",{"date":82,"type":21},"2030-02",{"name":84,"class":46},"Myotonic Dystrophy Foundation"]